Literature DB >> 10480196

Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia.

H Häfner1, W Löffler, K Maurer, M Hambrecht, W an der Heiden.   

Abstract

OBJECTIVE: The aim of this study was to investigate when social consequences in schizophrenia emerge, and what conditions give rise to the social disadvantage evident in people suffering from schizophrenia.
METHOD: Early course in schizophrenia was studied in a population-based sample of 232 first illness-episode cases retrospectively from onset to first admission, and in a representative subsample of 115 patients prospectively at six cross-sections over a period of 5 years. Data on non-specific and negative symptomatology and social development was compared with data from an age- and sex-matched control group drawn from the normal population.
RESULTS: In total, 73% of the patients showed a prodromal phase of several years. First signs were depressive and negative symptoms. In 57% of cases social disability emerged 2 to 4 years before first admission. Social consequences depended on the level of social development at onset. An early onset involved social stagnation, and a late onset was associated with social decline. Men's poorer social outcome was determined by their lower level of social development at onset and socially adverse illness behaviour. The 5-year symptom-related course showed no gender difference. At 81% the lifetime prevalence of depressive mood until first admission was several times higher in schizophrenics than in healthy controls. Early depression predicted a lower subsequent score for affective flattening. Suicide indicators were predicted by lack of self-confidence and feelings of guilt early in the illness.
CONCLUSION: Taking into account a prodromal phase of several years on average before first hospital admission, early detection, case identification and intervention are urgently needed. The intervention must be targeted at syndromes such as early depression, negative symptoms and certain forms of cognitive and social impairment.

Entities:  

Mesh:

Year:  1999        PMID: 10480196     DOI: 10.1111/j.1600-0447.1999.tb10831.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  87 in total

1.  The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe.

Authors:  Joachim Klosterkötter; Stephan Ruhrmann; Frauke Schultze-Lutter; Raimo K R Salokangas; Don Linszen; Max Birchwood; Georg Juckel; Anthony Morrison; José Luis Vázquèz-Barquero; Martin Hambrecht; Heinrich VON Reventlow
Journal:  World Psychiatry       Date:  2005-10       Impact factor: 49.548

2.  Prodromal schizophrenia in primary care: a randomised sensitisation study.

Authors:  Andor E Simon; Sabrina Jegerlehner; Thomas Müller; Katja Cattapan-Ludewig; Peter Frey; Marcus Grossenbacher; Erich Seifritz; Daniel Umbricht
Journal:  Br J Gen Pract       Date:  2010-09       Impact factor: 5.386

3.  Incidence of hospitalised schizophrenia in Finland since 1980: decreasing and increasing again.

Authors:  Raimo K R Salokangas; Mika Helminen; Anna-Maija Koivisto; Helena Rantanen; Hannu Oja; Sami Pirkola; Kristian Wahlbeck; Matti Joukamaa
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-03-20       Impact factor: 4.328

Review 4.  Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

Review 5.  Developing services for the early detection of psychosis: a critical consideration of the current state of the art.

Authors:  Andor E Simon; Binia Roth; Solange Zmilacher; Emanuel Isler; Daniel Umbricht
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-09-08       Impact factor: 4.785

6.  The recognition and optimal management of early psychosis: an evidence-based reform.

Authors:  Patrick D McGorry
Journal:  World Psychiatry       Date:  2002-06       Impact factor: 49.548

7.  Identifying a treatable psychosis-risk cohort.

Authors:  Jean Addington
Journal:  Can J Psychiatry       Date:  2013-01       Impact factor: 4.356

8.  Comorbid depressive symptoms in the developmental course of adolescent-onset psychosis.

Authors:  Marina Myles-Worsley; Starla Weaver; Francisca Blailes
Journal:  Early Interv Psychiatry       Date:  2007-08-15       Impact factor: 2.732

9.  Clinical correlates of subsyndromal depression in African American individuals with psychosis: The relationship with positive symptoms and comorbid substance dependence.

Authors:  Emma E M Knowles; Samuel R Mathias; Godfrey D Pearlson; Jennifer Barrett; Josephine Mollon; Dominique Denbow; Katrina Aberzik; Molly Zatony; David C Glahn
Journal:  Schizophr Res       Date:  2018-10-26       Impact factor: 4.939

10.  Symptom dimensions and functional impairment in early psychosis: more to the story than just negative symptoms.

Authors:  Daniel Fulford; Tara A Niendam; Erin G Floyd; Cameron S Carter; Daniel H Mathalon; Sophia Vinogradov; Barbara K Stuart; Rachel L Loewy
Journal:  Schizophr Res       Date:  2013-04-12       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.